Close Menu

NEW YORK – HTG Molecular Diagnostics plans to use its newly developed whole-transcriptome gene expression profiling platform, internally called WTTx, to develop oncology assays as well as tests for autoimmune disorders and infectious diseases.

The Tucson, Arizona-based firm expects to launch an early-access program by the end of the year, followed by a full commercial release of the platform in mid-2021.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.